The%20%u2018very%2C%20very%20bad%20look%u2019%20of%20remdesivir%2C%20the%20first%20FDA-approved%20COVID-19%20drug%20%7C%20Science%20%7C%20AAAS

The%20%u2018very%2C%20very%20bad%20look%u2019%20of%20remdesivir%2C%20the%20first%20FDA-approved%20COVID-19%20drug%20%7C%20Science%20%7C%20AAAS: October%20was%20a%20good%20month%20for%20Gilead%20Sciences%2C%20the%20giant%20manufacturer%20of%20antivirals%20headquartered%20in%20Foster%20City%2C%20California.%20On%208%20October%2C%20the%20company%20inked%20an%20agreement%20to%20supply%20the%20European%20Union%20with%20its%20drug%20remdesivir%20as%20a%20treatment%20for%20COVID-19%u2014a%20deal%20potentially%20worth%20more%20than%20%241%20billion.%20Two%20weeks%20later%2C%20on%2022%20October%2C%20the%20U.S.%20Food%20and%20Drug%20Administration%20%28FDA%29%20approved%20remdesivir%20for%20use%20against%20the%20pandemic%20coronavirus%20SARS-CoV-2%20in%20the%20United%20States%u2014the%20first%20drug%20to%20receive%20that%20status.%20The%20EU%20and%20U.S.%20decisions%20pave%20the%20way%20for%20Gilead%u2019s%20drug%20into%20two%20major%20markets%2C%20both%20with%20soaring%20COVID-19%20cases.%0A%0A